MoonLake Immunotherapeutics (MLTX) News Today $52.40 +0.51 (+0.98%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$52.38 -0.02 (-0.04%) As of 08/8/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is MoonLake Immunotherapeutics Up Today?Toggle Visibility of Why Is MoonLake Immunotherapeutics Up Today?Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) declined after several research firms cut their Q3 2025 earnings forecasts, putting pressure on the stock. Negative Sentiment: Leerink Partners trimmed its Q3 EPS estimate to ($0.96) from ($0.80). Leerink Partnrs Issues Negative Estimate for MLTX Earnings Negative Sentiment: Lifesci Capital lowered its Q3 EPS forecast to ($0.91) from ($0.70). Lifesci Capital Has Negative Forecast for MLTX Q3 Earnings Negative Sentiment: Wedbush cut its Q3 EPS estimate to ($0.88) from ($0.74) but maintained an Outperform rating with an $80 price target. Wedbush Has Pessimistic Outlook of MLTX Q3 Earnings Posted 1h agoAI Generated. May Contain Errors. MLTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Leerink Partnrs Issues Negative Estimate for MLTX EarningsAugust 9 at 8:30 AM | marketbeat.comLifesci Capital Has Negative Forecast for MLTX Q3 EarningsAugust 9 at 8:09 AM | marketbeat.comWedbush Issues Pessimistic Estimate for MLTX EarningsAugust 9 at 2:37 AM | americanbankingnews.comWedbush Has Pessimistic Outlook of MLTX Q3 EarningsAugust 8 at 8:26 AM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target Raised to $82.00 at The Goldman Sachs GroupAugust 7 at 11:43 AM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Issues Earnings Results, Misses Expectations By $0.14 EPSAugust 6 at 3:56 PM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Holdings Lifted by Westfield Capital Management Co. LPAugust 6 at 5:38 AM | marketbeat.comEnvestnet Asset Management Inc. Acquires 5,254 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)August 6 at 3:08 AM | marketbeat.comBeyond the Balance Sheet: What SWOT Reveals About MoonLake Immunotherapeutics (MLTX)August 5, 2025 | gurufocus.comMoonLake Immunotherapeutics Updates on Phase 3 VELA Program and Financial Results for Q2 2025August 5, 2025 | quiverquant.comQMoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business UpdateAugust 5, 2025 | globenewswire.comBIT Capital GmbH Has $571,000 Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)August 4, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Sells 5,351 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)August 3, 2025 | marketbeat.comAnalysts Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $73.14August 3, 2025 | americanbankingnews.comTD Asset Management Inc Sells 44,730 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)August 2, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Holdings Decreased by Federated Hermes Inc.August 1, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 31, 2025 | marketbeat.comMoonLake Immunotherapeutics (MLTX) Projected to Post Quarterly Earnings on WednesdayJuly 30, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to "Hold" at Redburn AtlanticJuly 29, 2025 | marketbeat.comMoonLake initiated with a Neutral at Rothschild & Co RedburnJuly 28, 2025 | msn.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Coverage Initiated by Analysts at Rothschild & Co RedburnJuly 28, 2025 | marketbeat.comMoonLake Immunotherapeutics (MLTX) Receives Neutral Rating from RedburnJuly 28, 2025 | gurufocus.comNew York State Common Retirement Fund Buys New Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX)July 27, 2025 | marketbeat.comTraders Buy Large Volume of MoonLake Immunotherapeutics Put Options (NASDAQ:MLTX)July 26, 2025 | marketbeat.comLegato Capital Management LLC Makes New $240,000 Investment in MoonLake Immunotherapeutics (NASDAQ:MLTX)July 26, 2025 | marketbeat.comVictory Capital Management Inc. Grows Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)July 25, 2025 | marketbeat.comRice Hall James & Associates LLC Purchases 26,383 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)July 14, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Buy" from BrokeragesJuly 6, 2025 | marketbeat.comMoody Aldrich Partners LLC Makes New $2.16 Million Investment in MoonLake Immunotherapeutics (NASDAQ:MLTX)July 4, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 2.7% - Here's WhyJuly 3, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by Harbor Capital Advisors Inc.June 11, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of "Buy" by AnalystsJune 11, 2025 | marketbeat.comCantor Fitzgerald Forecasts MLTX FY2026 EarningsJune 10, 2025 | marketbeat.comMoonLake Immunotherapeutics (MLTX) Hosts Investor Meetings Amid Merger Speculation | MLTX Stock NewsJune 9, 2025 | gurufocus.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCJune 7, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 3.9% - What's Next?June 6, 2025 | marketbeat.comMoonLake Immunotherapeutics Breaks Above 200-Day Moving Average - Bullish for MLTXJune 5, 2025 | nasdaq.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Large Volume Increase - Here's WhyJune 4, 2025 | marketbeat.comWellington Management Group LLP Lowers Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX)June 4, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Takes Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)June 4, 2025 | marketbeat.comMoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma InterestJune 3, 2025 | seekingalpha.comConstellation and Meta, Merck, Snowflake: Trending TickersJune 3, 2025 | finance.yahoo.comMoonLake Immunotherapeutics Catapults On Rumored Merck TakeoverJune 3, 2025 | msn.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up - Here's What HappenedJune 3, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Outperform Rating from Royal Bank of CanadaJune 3, 2025 | marketbeat.comMerck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: ReportJune 3, 2025 | benzinga.comMerck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: ReportJune 3, 2025 | finance.yahoo.comMoonLake Immunotherapeutics stock surges on FT report of Merck buyout talksJune 2, 2025 | investing.comMerck held talks to buy biotech MoonLake for over $3 billion, FT reportsJune 2, 2025 | reuters.comBank of America Corp DE Sells 76,559 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)June 2, 2025 | marketbeat.com Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address MLTX Media Mentions By Week MLTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLTX News Sentiment▼0.040.49▲Average Medical News Sentiment MLTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLTX Articles This Week▼235▲MLTX Articles Average Week Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRNA News Today RDY News Today QGEN News Today VTRS News Today ASND News Today BBIO News Today VRNA News Today BPMC News Today LEGN News Today ROIV News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLTX) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
